Pluri Receives US Patent for Immune Cell Expansion-November 2024-www.financetom.com

Pluri Receives US Patent for Immune Cell Expansion

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Pluri Receives US Patent for Immune Cell Expansion

Apr 8, 2024 10:39 AM

01:16 PM EDT, 04/08/2024 (MT Newswires) -- Pluri ( PLUR ) said Monday it has received a new US patent for technology used in the expansion of immune cells.

The new patent addresses challenges in allogeneic cell therapies, including limited donor cell availability, the company said.

Price: 5.44, Change: +0.02, Percent Change: +0.37

Previous page： Deals of the day-Mergers and acquisitions Next page：

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Deals of the day-Mergers and acquisitions

Feb 13, 2025

Feb 13 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1030 GMT on Thursday: ** AsiaPak Investments, a private investment firm with operational assets in Pakistan and Hong Kong, and Middle Eastern oil and gas company Motange Oil have submitted a bid to acquire a 75.01% stake in Lotte Chemical Pakistan Ltd (LOTT.PSX), according to a...

Feb 13, 2025

...

Euronet Worldwide Q4 Adjusted Profit, Revenue Rise

Feb 13, 2025

06:01 AM EST, 02/13/2025 (MT Newswires) -- Euronet Worldwide ( EEFT ) reported late Wednesday Q4 adjusted profit of $2.08 per share, up from $1.88 per share a year earlier. Revenue for the quarter ended Dec. 31 was $1.05 billion, up from $957.7 million a year earlier. Analysts polled by FactSet expected $1.04 billion. ...

J&J to discontinue E.coli vaccine candidate study

Feb 13, 2025

Feb 13 (Reuters) - Johnson & Johnson ( JNJ ) on Thursday said it will discontinue a late-stage study of an experimental E.coli vaccine that it was developing in partnership with Sanofi . The drugmaker said its decision was based on the recommendation of an independent committee that found the vaccine candidate may not be sufficiently effective. ...